Leucine-rich repeat containing G-protein coupled receptor 5 (LGR5) is a seven-transmembrane protein recently identified as a marker of normal stem cells in several tissues including the intestine ([@bib3]). LGR5 functions in the modulation of Wnt/*β*-catenin signalling, a vital pathway in stem cell biology and tissue homeostasis. LGR5 binds extracellular R-spondins at the cell membrane ([@bib5]; [@bib8]) and subsequently associates with Wnt receptors to increase Wnt/*β*-catenin signalling ([@bib10]; [@bib6]). Multiple studies have proposed that LGR5 identifies tumour-initiating cells, or promotes 'stemness\' in colorectal cancer (CRC) ([@bib2]; [@bib15]; [@bib16]; [@bib24]; [@bib12]). Further studies suggest a pro-survival role in CRC cells, thus raising the potential of LGR5 as a therapeutic target in CRC ([@bib1]; [@bib12]; [@bib13]). Nutrient deprivation occurs in a developing tumour when the metabolic demand exceeds that suppliable by the local vasculature ([@bib26]). Such microenvironmental stresses can force molecular adaptations which promote a survival rather than proliferative response, resulting in clonal selection of a more malignant phenotype ([@bib28]; [@bib23]). Despite the importance of LGR5 to stem cell biology, little is known about how expression and subcellular localisation are affected in microenvironmental pressures, such as nutrient stress. In this study, we show for the first time that LGR5 is glycosylated and that glucose deprivation alters the glycosylation status of LGR5 affecting the stability and subcellular localisation of the molecule.

Materials and methods
=====================

Cell lines and culture
----------------------

The human colorectal adenoma-derived cell line RG/C2 was derived in this laboratory and maintained as described previously ([@bib20], [@bib21]; [@bib27]). The LS174t-LGR5 cell line (double HA/FLAG tag) was a kind gift from Hans Clevers ([@bib8]). All other colorectal cell lines were obtained from the American Type Culture Collection and maintained as previously described ([@bib19]).

Cell treatments
---------------

Deglycosylation of cell lysates by Endoglycosidase H (EndoH) and peptide N-glycosidase F (PNGaseF) was performed as previously described ([@bib18]). For *in vitro* inhibition of glycosylation, cells were treated with 0.1--10 *μ*g ml^−1^ tunicamycin (TMC; Sigma-Aldrich, Poole, UK) or the equivalent volume of DMSO vehicle control at 37 °C for 24, 48 and 72 h. For inhibition of protein synthesis, cells were treated with 10 *μ*g ml^−1^ cyclohexamide (Sigma), or the equivalent volume of water control, for 0--3 h. Glucose starvation was performed as previously described ([@bib23]).

Immunoblotting
--------------

Immunoblotting was performed as described previously ([@bib11]) using a previously validated rabbit monoclonal LGR5 antibody (ab75850, Abcam, Cambridge, UK) ([@bib1]).

Flow cytometry
--------------

For LGR5 surface staining, cells were immunolabelled with a previously validated primary rat anti-LGR5 antibody (4D11F8, Becton Dickinson, Oxford, UK) ([@bib15]) followed by secondary labelling with phycoerythrin-conjugated goat anti-rat IgG (BD). For total LGR5 staining, cells were fixed in 2% paraformaldehyde and permeabilised using 0.1% Triton X-100 prior to antibody addition as above. Multi-parameter flow cytometric measurements were performed using FACSCanto II cytometer (BD) in conjunction with FACS Diva software v8.0 (BD). 7AAD (BD) was used to assess cell viability and the threshold for positive LGR5 staining was determined using the appropriately matched isotype control antibody (BD). Post-acquisition analyses were performed using FlowJo software vX.0.6 (Tree Star Inc, Ashland, OR, USA).

Confocal laser scanning microscopy
----------------------------------

Colorectal cancer cells were grown on glass coverslips for 72 h prior to DMSO control or TMC treatment. Treated cells were then stained for both total and surface LGR5 as above (see \'Flow Cytometry\') except an Alexa488 goat anti-rat secondary antibody (Invitrogen, Paisley, UK) was preferred. Cells were co-stained with sheep anti-Grasp65 (Jon Lane, Bristol University) and Alexa647-conjugated anti-E-cadherin (cell membrane marker; BD) antibodies. Grasp65-stained cells were detected using an Alexa594-conjugated donkey anti-sheep secondary antibody (Invitrogen). All cells were counter-stained with DAPI prior to mounting. Confocal laser scanning microscopy was performed as previously described ([@bib22]) and images were generated without any post-acquisition manipulation using LAS AF v2.6.0 (Leica Microsystems, Milton Keynes, UK). Co-localisation quantification analyses were performed using Volocity confocal software v6.3.0 (Perkin-Elmer, Waltham, MA, USA).

Real-time polymerase chain reaction
-----------------------------------

Analysis of LGR5 mRNA was performed as previously described ([@bib1]).

Statistics
----------

All statistical analyses were performed using GraphPad Prism v5.01 (GraphPad Software, Inc., San Diego, CA, USA). Significance of difference was assessed using one-sample or students *t-*test with significance defined at *P*\<0.05.

Results
=======

To examine how tumour microenvironmental pressures such as nutrient stress affect LGR5 expression, we placed CRC cells into glucose-starved conditions. Following 16 h of glucose deprivation, both LoVo and LS174t-LGR5 cells not only demonstrated reduced expression of LGR5 but also exhibited a 10--20 kDa lower molecular weight form of LGR5 ([Figure 1A](#fig1){ref-type="fig"}). Such protein mobility shifts can be the result of heavy posttranslational modifications such as glycosylation. Upon its initial characterisation, four consensus *N*-linked glycosylation sites were identified in the ectodomain of LGR5 ([@bib14]). Furthermore, using publicly available glycosylation site prediction software (NetNGlyc 1.0 Server, Technical University of Denmark, <http://www.cbs.dtu.dk/services/NetNGlyc> ([@bib4])), we identified six potential glycosylation sites in the LGR5 amino acid sequence, three of which had strong confidence in the ectodomain. To formally explore the glycosylation status of LGR5, we treated cell lysate from LGR5-expressing colorectal tumour (CRT) cell lines with endoglycosidases that remove specific types of glycosylation. While EndoH removes immature forms only, PNGaseF removes all forms of *N*-linked glycosylation. A panel of CRT cell lines were selected representing various stages of CRT progression including RG/C2 (adenoma), LS174t (carcinoma), SW620 and LoVo (advanced metastatic carcinoma). Treatment with either EndoH or PNGaseF resulted in a 10--20 kDa molecular weight reduction in the LGR5 protein across all cell lines examined indicating LGR5 is glycosylated ([Figure 1B](#fig1){ref-type="fig"}). Across all CRT cell lines, there remained a readily detectable EndoH-resistant LGR5 protein at 99 kDa confirming that both mature and immature glycosylated LGR5 protein are abundant within CRT cells. This is unsurprising given the very short half-life of LGR5 protein, which we estimated to be approximately 1 h using cyclohexamide treatment ([Figure 1C](#fig1){ref-type="fig"}). To examine the consequence of altered glycosylation status on expression and subcellular distribution of LGR5, it was important to be able to inhibit LGR5 glycosylation in living cells. To achieve this, we treated cells with an escalating dose of TMC, which broadly inhibits all *N*-linked glycosylation. As observed in [Figure 1D](#fig1){ref-type="fig"}, LGR5 glycosylation was optimally inhibited at 1 *μ*g ml^−1^ TMC in most cell lines except for SW620 cells, which required a higher concentration of 5 *μ*g ml^−1^. This is evidenced by the 10--20 kDa loss in LGR5 molecular weight and reduced protein stability as previously observed with glucose deprivation ([Figure 1D](#fig1){ref-type="fig"}). We confirmed the above observations were likely due to a posttranslational modification of LGR5 by showing that LGR5 mRNA expression was not significantly affected by glucose starvation or TMC treatment ([Figure 1E](#fig1){ref-type="fig"}).

To examine the significance of LGR5 glycosylation status for its subcellular distribution within tumour cells, we treated CRT cell lines with TMC and assessed both total and cell surface LGR5 level by flow cytometry. TMC treatment significantly reduced total LGR5 levels in LoVo and LS174t-LGR5 cell lines by 67.7%±12.4% and 45.6%±15.2%, respectively ([Figure 2A](#fig2){ref-type="fig"}). In comparison, cell surface LGR5 protein level was highly significantly diminished with TMC treatment in both cell lines. Disproportional to total LGR5 level, cell surface LGR5 was reduced by 98.7%±1.9% and 90.8%±6.6% for LoVo and LS174t-LGR5 cell lines, respectively ([Figure 2B](#fig2){ref-type="fig"}). To confirm these findings, we used confocal laser scanning microscopy which demonstrated that LGR5 membrane expression was dramatically reduced in both TMC-treated LoVo and LS174t-LGR5 cells ([Figure 2C and D](#fig2){ref-type="fig"}, respectively). Detection of E-cadherin in LoVo cells served not only as a membrane marker, but also demonstrated that TMC treatment does not universally deplete cell surface expression of all glycosylated membrane proteins such as E-cadherin ([Figure 2E](#fig2){ref-type="fig"}) ([@bib29]). Detection of E-cadherin in the LS174t cell line was not possible in keeping with a previously reported *CDH1* mutation ([@bib9]). To confirm that TMC treatment affected LGR5 in a similar manner to nutrient stress, we repeated our flow cytometry experiments in [Figure 2A](#fig2){ref-type="fig"} but with glucose starvation and also observed significantly depleted LGR5 surface expression ([Figure 2F](#fig2){ref-type="fig"}). We also confirmed that 16-h glucose deprivation did not alter cell viability ([Figure 2G](#fig2){ref-type="fig"}).

Following initial glycosylation events in the endoplasmic reticulum, newly synthesised proteins are transported to the cis-Golgi network where further glycosylation trafficks the protein to the appropriate subcellular compartment. Using Grasp65 as a marker of the cis-Golgi network ([@bib7]), we examined LGR5 localisation after inhibition of glycosylation. For both DMSO control-treated LoVo and LS174t-LGR5 cells, intracellular LGR5 staining presented mainly as large intracellular puncta within the cytoplasm and perinuclear regions ([Figure 3A and B](#fig3){ref-type="fig"}, respectively) as previously reported ([@bib15]; [@bib25]). A substantial proportion of the LGR5 signal co-localised with Grasp65 as indicated by areas of white co-fluorescence. In TMC-treated LoVo cells, the overall LGR5 signal was clearly reduced as previously observed in flow cytometry and immunoblot experiments, again suggesting reduced overall protein stability. However, the remaining LGR5 signal appeared more dispersed within the cytoplasm with several Grasp65-positive regions devoid of any LGR5 co-staining ([Figure 3A and B](#fig3){ref-type="fig"}). Co-localisation quantification analyses using both Pearson\'s Correlation Coefficient and Mander\'s Colocalisation Coefficient ([@bib17]) confirmed these observations. For both LoVo and LS174t-LGR5 cells, there existed a strong positive correlation between LGR5 and Grasp65 signal which was significantly weakened upon TMC treatment in both cell lines ([Figure 3C and D](#fig3){ref-type="fig"}, respectively). These data indicate that the absence of *N*-linked glycosylation results in a lower proportion of LGR5 localised within the cis-Golgi network, consistent with the notion that incorrectly folded proteins are not trafficked to the Golgi.

Discussion
==========

This study shows for the first time that LGR5 is glycosylated and importantly that nutrient stress can alter the glycosylation status of LGR5 resulting in reduced protein stability and membrane localisation in CRT cells. The main LGR5 stem cell function described to date is in the regulation of Wnt signalling through capturing of R-Spondins and complexing with the Wnt receptors Frz and LRP5/6 ([@bib5]; [@bib8]). Therefore, glycosylation represents a critical posttranslational modification allowing LGR5 to perform these, and other potential uncharacterised functions at the membrane. It is conceivable that a tumour-initiating cell, within a glucose-deprived microenvironment, could obtain a competitive advantage through reduced LGR5 surface levels, by directing the cell into a pro-survival mode rather than the proliferative response associated with Wnt signalling promotion. This study also has implications for targeting cancer stem cells through surface markers, such as LGR5, because surface expression is significantly reduced by fluctuating tumour microenvironmental pressures such as nutrient stress.
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![The glycosylation status of the LGR5 protein can be modified by glucose starvation and *in vitro* treatments. (**A**) Immunoblots showing LGR5 protein migration patterns from LoVo and LS174t-LGR5 cells cultured in glucose containing (+) and non-glucose containing (−) culture medium for 16 h. *α*-Tubulin indicates comparable protein loading amongst samples whereas adjacent right-side arrowheads and numbers indicate position of molecular weight markers (kDa) on blots. (**B**) Immunoblots showing LGR5 protein migration patterns from various CRT cell lines in response to endoglycosidase treatment or PBS control. Adjacent right-side arrows indicate the location of LGR5 forms either resistant (Res) or sensitive (Sens) to endoglycosidase treatment. Adjacent left-side arrowheads and numbers indicate position of molecular weight markers (kDa) on blots. Exposure times vary between all blots in order to clearly show LGR5 banding pattern and are thus not representative of relative LGR5 expression amongst the cell lines. Note the higher molecular weight of exogenous LGR5 protein in the LS174t-LGR5 line due to the presence of a double HA/FLAG tag. (**C**) Immunoblot showing LGR5 expression in LoVo cells treated with 10 *μ*g ml^−1^ cyclohexamide or the equivalent water vehicle control for 0--3 h. *α*-Tubulin indicates comparable protein loading amongst samples. (**D**) Immunoblots showing LGR5 protein band conformation from CRT cell lines treated for 24 h with increasing doses of TMC. (**E**) Quantitative real-time PCR analysis of LGR5 mRNA in LoVo and LS174t-LGR5 cells following 16 h of glucose starvation (GS) or 24 h TMC treatment. Data represent mean±1 s.d., *n*=3. Statistical significance is denoted by \*\**P*\<0.01, \*\*\**P*\<0.001 and NS=not significant as analysed by one-sample *t*-test.](bjc20154f1){#fig1}

![Inhibiting glycosylation of LGR5 results in severely depleted cell surface expression. Representative flow cytometric histograms and associated summary graphs demonstrating the (**A**) total or (**B**) cell surface expression of LGR5 in response to 24 h DMSO control (Cont) or 1 *μ*g ml^−1^ TMC treatment. Representative confocal laser scanning microscopy Z-sections showing LGR5 cell surface expression in (**C**) LoVo and (**D**) LS174t-LGR5 cells following 24 h DMSO control (Cont) or 1 *μ*g ml^−1^ TMC treatment. LGR5 (green), E-cadherin (E-Cad; red), DAPI (blue) and Phase (grey) images are shown. Data shown are representative of 20 fields each derived from three independent experiments. (**E**) Quantification of total and cell surface E-cadherin mean fluorescence from control and TMC treated LoVo cells as analysed by confocal laser scanning microscopy. (**F**) Representative flow cytometric histograms and associated summary graphs showing the cell surface expression of LGR5 in LoVo and LS174t-LGR5 cells following 16 h glucose starvation (GS). (**G**) Flow cytometric assessment of percentage viability in control and glucose-starved cultures (\>80% as deduced from 7AAD dye). For all graphs, data represent mean±1 s.d., *n*=3. Statistical significance is denoted by \*\**P*\<0.01, \*\*\**P*\<0.001 and NS=not significant as analysed by one-sample *t*-test.](bjc20154f2){#fig2}

![Inhibiting LGR5 glycosylation results in reduced localisation within the cis-Golgi network. Confocal laser scanning microscopy Z-sections showing intracellular LGR5 expression in fixed and permeabilised (**A**) LoVo and (**B**) LS174t-LGR5 cells following 24 h treatment with DMSO control or 1 *μ*g ml^−1^ TMC. Merged (LGR5 and Grasp65 only), LGR5 (green), Grasp65 (G65; magenta), E-cadherin (E-Cad; red) and DAPI (blue) images are shown. Areas of co-localisation between LGR5 and Grasp65 are indicated by resulting white colour (highlighted by arrowheads). Overall correlation between LGR5 and Grasp65 signal in DMSO control or TMC treated (**C**) LoVo and (**D**) LS174t-LGR5 cells, as determined by thresholded Pearsons Correlation Coefficient (−1= inverse correlation, 0= no correlation, +1= positive correlation). Proportion of Grasp65 signal co-localised with LGR5 fluorescence in DMSO control or TMC treated cells is also shown as determined by the Mander\'s Colocalisation Coefficient. Data represent mean ±1 s.d. as deduced from a minimum of 20 random fields, *n*=3. Statistical significance is denoted by \*\*\**P*\<0.001, as analysed by students *t*-test.](bjc20154f3){#fig3}
